Targeting cancer with power and precision


Eleven Biotherapeutics, Inc. (NASDQ: EBIO) is a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on the company's targeted protein therapeutics (TPTs) platform. The company believes its TPTs can potentially offer significant advantages in treating cancer versus existing antibody drug conjugate technologies. Eleven’s approach to drug design creates TPTs that it believes facilitate effective tumor targeting with cancer cell-killing properties unique to protein payloads versus small molecules. The ability of TPTs cancer cell-killing properties to promote an anti-tumor immune response suggest that TPTs will potentially combine well with immune oncology drugs.

 

In September of 2016, Eleven announced the acquisition of Viventia Bio Inc. Eleven’s pipeline now includes Viventia’s lead product candidates Vicinium and Proxinium.

 


Year Invested: 2010
Location: Cambridge, Mass.
Visit: www.elevenbio.com

Recent News

May 17, 2017
Eleven Biotherapeutics Continues Expansion of Clinical Development Team with Appointment of David Brooks, M.D., Ph.D., to Senior Vice President, Clinical Development

May 4, 2017
Eleven Biotherapeutics Reports First Quarter 2017 Financial Results

April 28, 2017
Eleven Biotherapeutics to Report First Quarter 2017 Financial Results on Thursday, May 4, 2017

Read More News

Associated Team Members

Mark Levin
Partner

Cary Pfeffer, M.D.
Partner

Abbie Celniker, Ph.D.
Partner